A controversial stance by fitness influencer and BJJ practitioner Dr. Mike Israetel has sparked debate in the medical community. He suggested that “most adults should consider taking Tirzepatide, even if they aren’t overweight.”
The Instagram post, which Israetel described as his “wacky but evidence-based opinion,” claims the medication’s non-weight mediated health benefits are so substantial that most people would be healthier taking it.
Dr. Spencer Nadolsky, a triple board-certified obesity specialist, has offered a comprehensive response to Israetel’s claims in a YouTube video. He highlighted both the problems and potential merits of this position. Nadolsky’s primary criticism centers on the use of “evidence-based” terminology when advocating for medication use in populations that haven’t been adequately studied.
“The biggest issue I have with this statement is the combination of the term evidence-based along with the fact that he’s advocating for people to take this even when not overweight,” Nadolsky explains. Current clinical trials for Tirzepatide have focused exclusively on populations with type 2 diabetes or those with overweight and obesity, leaving normal-weight, healthy individuals in what he calls “an evidence-free zone.”
Despite these concerns, Nadolsky acknowledges the potential validity of Israetel’s hypothesis when viewed through a broader lens. He notes that many seemingly normal-weight individuals may actually suffer from “clinical obesity” – experiencing harm from excess fat tissue despite appearing healthy by traditional BMI measurements. When considering that most American adults have overweight or obesity, Israetel’s “most people” qualifier becomes more defensible.
Nadolsky’s clinical experience reveals promising off-label applications for GLP-1 medications beyond weight management. Patients have reported significant improvements in alcohol use disorder, with many experiencing reduced cravings almost immediately. The medication has also shown superior effectiveness for binge eating disorders compared to traditional treatments like SSRIs and Topamax.
Women with polycystic ovarian syndrome (PCOS), including those with the lean phenotype, have experienced cycle improvements and symptom relief without weight loss. Perhaps most intriguingly, patients with autoimmune inflammatory conditions like rheumatoid arthritis and Crohn’s disease have reported substantial pain reduction and overall wellness improvements, even when weight remained stable.
Looking toward the future, Nadolsky envisions these medications being used for cardiovascular disease prevention in both high-risk individuals and potentially as primary prevention in lean, healthy people. The most compelling application may be preventing obesity in those with strong family histories of weight-related complications.
However, Nadolsky emphasizes caution, noting that lean individuals would require subtherapeutic doses, and the efficacy of these lower doses remains unknown. He advocates for a measured approach: “Let’s be cautious but optimistic. I do not recommend these medicines in people that don’t have proper indications.”
While Nadolsky doesn’t currently take these medications himself despite having “a lot of food noise,” he acknowledges a possible future where evidence might support their use for heart attack prevention in lean, healthy individuals.
